APAC Transcatheter Aortic-Valve Replacement Market by Product Type (balloon-expandable TAVR Device, Self-Expanding TAVR Device, and Others), By Procedure Type (Transfemoral Implantation, Transapical Implantation, Transaortic Implantation), By End-Use (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, and Others) and by Region – APAC Forecast to 2032

APAC Transcatheter Aortic-Valve Replacement Market Overview:

The APAC Transcatheter Aortic-Valve Replacement market is projected to be USD 319.6 Mn in 2021 to reach USD 1,092.2 Mn by 2030 at a CAGR of 14.6%.

Market.US announces the publication of its most recently generated research report titled, “APAC Transcatheter Aortic-Valve Replacement by Product Type (balloon-expandable TAVR Device, Self-Expanding TAVR Device, Mechanically-Expandable TAVR Devices), By Procedure Type (Transfemoral Implantation, Transapical Implantation, Transaortic Implantation), By End-Use (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Research/Academic Institutes) and by Region – APAC Forecast to 2031”, which offers a holistic view of the APAC Transcatheter Aortic-Valve Replacement through systematic segmentation that covers every aspect of the target market.

Transcatheter aortic valve replacement (TAVR), also known as percutaneous aortic valve replacement (PAVR) or percutaneous aortic valve implantation (PAVI), is the replacement of the aortic valve of the heart through blood vessels.

Patients with severe aortic stenosis have a high mortality rate without any intervention, and until recently did they require open-heart surgery or aortic valve replacement. This operation has a high risk for elderly patients and patients with chronic kidney disease, chronic respiratory dysfunction, etc. In this case, TAVR is the first choice to relieve the symptoms and signs of aortic stenosis and may improve patient survival. People with severe symptoms.

APAC Transcatheter Aortic-Valve Replacement Market Revenue (US$ Mn), 2021–2030

Aortic valve stenosis is closely related to aging. The global population is aging and increasing, especially in developed countries such as the United States, Europe, and Japan. It is estimated that by 2050, the global aging population will rise from 11% (760 million) in 2011 to 22% (2 billion). This is another factor that is expected to support the growth of the target market.

Although the risks associated with TAVR surgery are low, there are still certain side effects and risks, which may be common after surgery. These risks include bleeding, vascular complications, arrhythmia, infection, kidney or heart disease, heart attack, stroke, and even death, which may inhibit market growth to a certain extent.

Nonetheless, the risks associated with these implants are relatively lower than open-heart surgery, which may inhibit the impact of this challenge.

APAC Transcatheter Aortic-Valve Replacement Market Attractiveness Analysis by Type, 2015–2030

Asia-Pacific transcatheter aortic valve replacement (TAVR) market is segmented on the basis of product type, procedure type, end-use, and country. On the basis of product type, the market is segmented into balloon-expandable TAVR devices, self-expanding TAVR devices, and mechanically-expandable TAVR devices.

On the basis of procedure type, the market is bifurcated into transfemoral implantation, transapical implantation, and transaortic implantation. The transfemoral implantation segment accounts for the highest revenue, owing to the procedure being standardized for aortic stenosis.

On the basis of end-use, the market is segmented between hospitals, ambulatory surgical centers, specialty clinics, and research/ academic institutes. Amongst the regional segment, the market is divided into China, Japan, South Korea, India, and the Rest of Asia-Pacific. Japan accounts for the majority share in the market, owing to insurance coverage provided for such procedures by the Government.

The research report on the APAC Transcatheter Aortic-Valve Replacement market includes profiles of some of the major companies such as:

• Medtronic Plc
• Meril Life Sciences Pvt. Ltd
• NVT Ag
• Venus Medtech (Hangzhou), Inc.
• and others.

Asia-Pacific Transcatheter Aortic Valve Replacement (TAVR) Market segmentation on the basis of Product Type, Procedure Type, End-Use, and Country:

Product Type:

• Balloon-expandable TAVR devices
• Self-expanding TAVR devices
• Mechanically-expandable TAVR devices

Procedure Type:

• Transfemoral implantation
• Transapical implantation
• Transaortic implantation

End-Use:

• Hospitals
• Ambulatory surgical centers
• Specialty clinics
• Research/ Academic institutes

Country:

• China
• Japan
• South Korea
• India
• Rest of Asia-Pacific

For the APAC Transcatheter Aortic-Valve Replacement Market research study, the following years have been considered to estimate the market size: